PDLIM2 and lung carcinoma: Our analysis revealed that lung cancer patients with high PDLIM2 expression and received AT showed better overall survival and recurrence-free survival compared to those patients with low PDLIM2 expression and received AT, and those patients with high PDLIM2 expression but did not receive AT (Fig. 4b, c).